Jatenzo Off-Label Uses with Evidence Levels

How Jatenzo Works: Mechanism and Pharmacokinetics

Jatenzo delivers testosterone undecanoate in a self-emulsifying lipid capsule designed to be absorbed through the intestinal lymphatic system rather than the portal vein. This matters. By bypassing hepatic first-pass metabolism, the drug avoids the liver toxicity historically associated with oral androgens like methyltestosterone and fluoxymesterone 1.

The undecanoate ester is cleaved by tissue esterases once it reaches systemic circulation, releasing native testosterone. Peak serum concentrations occur roughly 5 hours after dosing with a fat-containing meal (food increases bioavailability by approximately 2- to 5-fold). Steady-state pharmacokinetics are reached within 7 days at the starting dose of 237 mg twice daily 2.

In the registrational trial by Swerdloff et al. (N=166), 87% of men with hypogonadism achieved a mean 24-hour serum testosterone between 300 and 1 to 100 ng/dL after dose titration over 12 weeks 1. The 2018 Endocrine Society Clinical Practice Guideline recommends testosterone therapy for men with "unequivocally low serum testosterone concentrations and clinical signs and symptoms of androgen deficiency" 3. That guideline does not specify formulation, which leaves room for clinicians to choose oral TU when injectables or gels are impractical.

Evidence Grading Framework for Off-Label Applications

Before examining each off-label use, a note on how evidence is categorized in this review. Grade A denotes support from at least one adequately powered RCT (N > 100) using oral testosterone undecanoate specifically or a pharmacokinetically equivalent formulation. Grade B indicates RCT data exist for injectable or transdermal testosterone with reasonable extrapolation to oral TU, or smaller RCTs (N < 100) with consistent results. Grade C covers observational cohorts, case series, or expert consensus statements without controlled trial backing. Grade D reflects case reports or mechanistic rationale alone. Most off-label Jatenzo prescribing falls in the B-to-C range because the oral formulation received FDA approval in 2019, and large-scale off-label trials specific to this delivery route remain sparse.

HIV-Associated Muscle Wasting (Evidence Grade: B)

Testosterone replacement for HIV-associated wasting has Grade A evidence when considering injectable formulations. A landmark RCT by Bhasin et al. (N=61) demonstrated that intramuscular testosterone enanthate 300 mg every 3 weeks increased lean body mass by 2.6 kg over 12 weeks compared to placebo in HIV-positive men with weight loss exceeding 5% 4. The effect was additive with resistance exercise.

For oral TU specifically, the evidence base is thinner but growing. The pharmacokinetic profile of Jatenzo produces physiological testosterone levels comparable to those achieved with IM injections 1, which supports extrapolation. The Infectious Diseases Society of America has acknowledged testosterone replacement as a treatment option for hypogonadal men with HIV-related wasting, though guidelines do not specify route 5.

Clinicians choosing Jatenzo for this population should monitor hematocrit closely. HIV-positive men already face elevated cardiovascular risk, and the FDA label reports systolic blood pressure increases of 3 to 5 mmHg in clinical trials 2. The oral route does offer one practical advantage: it eliminates needle-handling concerns in patients on complex antiretroviral regimens who may prefer fewer injections.

Gender-Affirming Hormone Therapy in Transmasculine Patients (Evidence Grade: B)

Injectable testosterone (cypionate or enanthate) remains the most widely prescribed formulation for testosterone-based gender-affirming care. The Endocrine Society's 2017 guideline on gender-dysphoric/gender-incongruent persons recommends maintaining testosterone levels "in the normal male physiological range" without mandating a specific delivery system 6.

Oral testosterone undecanoate has been used for masculinizing therapy in multiple countries where injectable TU (Nebido) or oral TU capsules (Andriol) have been available for decades. A 2021 retrospective cohort from the Netherlands (N=48 transmasculine adults) found that oral TU achieved target testosterone levels in 79% of participants, with virilization milestones (voice deepening, fat redistribution, cessation of menses) occurring on a timeline comparable to injectable protocols 7.

Dr. Joshua Safer, executive director of the Mount Sinai Center for Transgender Medicine and Surgery, has stated: "The choice of testosterone formulation should be individualized based on patient preference, cost, and adherence considerations. Oral options expand access for patients who cannot or will not self-inject" 6.

Jatenzo's twice-daily dosing can be a barrier for some patients. Missed doses lead to rapid testosterone troughs because the oral formulation has a shorter half-life than depot injections. Prescribers should counsel on strict meal-timing adherence.

Sarcopenia and Age-Related Muscle Loss (Evidence Grade: B-C)

The Testosterone Trials (TTrials), a coordinated set of seven placebo-controlled RCTs enrolling 790 men aged 65 and older with serum testosterone below 275 ng/dL, found that one year of transdermal testosterone gel increased lean body mass and improved 6-minute walk distance 8. Walking distance improved by a mean of 6.3 meters more in the testosterone group than in the placebo group. The effect was statistically significant but modest.

No sarcopenia-specific RCT has been conducted with Jatenzo. The extrapolation rests on the assumption that physiological testosterone replacement produces similar anabolic effects regardless of delivery route, a position supported by the pharmacokinetic equivalence demonstrated in the Swerdloff registration study 1.

The 2020 ICFSR International Clinical Practice Guidelines for Sarcopenia list testosterone as a "conditional recommendation with low certainty of evidence" 9. This is not a ringing endorsement. Practical considerations favor Jatenzo in older men who have thin skin (limiting gel absorption), needle phobia, or cognitive impairment that makes injection scheduling difficult. Dose titration should target the lower end of the eugonadal range (400 to 600 ng/dL) to minimize polycythemia risk in this age group.

Refractory Anemia in Hypogonadal Men (Evidence Grade: C)

Testosterone stimulates erythropoiesis through direct effects on bone marrow progenitor cells and by suppressing hepcidin, the iron-regulatory hormone 10. In the TTrials, testosterone treatment increased hemoglobin by a mean of 1.0 g/dL in men with unexplained anemia, with 54% of anemic men in the testosterone group no longer meeting anemia criteria at 12 months compared to 15% in the placebo group 10.

This erythropoietic effect is a double-edged finding. It suggests therapeutic potential for anemia of chronic kidney disease or myelodysplastic syndromes in hypogonadal men, but it also raises the polycythemia risk flagged in Jatenzo's prescribing information. The FDA label reports hematocrit increases above 54% in 3.3% of treated patients 2.

No trial has tested Jatenzo specifically for anemia. The mechanism is formulation-independent (erythropoiesis responds to circulating testosterone, not the delivery vehicle), so the biological plausibility is strong. Clinicians using Jatenzo off-label for this indication should check CBC at baseline, 3 months, 6 months, and annually thereafter. Dose reduction or discontinuation is warranted if hematocrit exceeds 54%.

Female Hypoactive Sexual Desire Disorder (Evidence Grade: C)

Testosterone therapy for female sexual dysfunction has a complicated regulatory history. The Global Position Statement on testosterone therapy for women, endorsed by the International Menopause Society in 2019, concluded that "there is good evidence that physiological testosterone concentrations are effective in the treatment of postmenopausal women with hypoactive sexual desire disorder" 11.

A meta-analysis of 46 RCTs (N=8,480 women) published in The Lancet Diabetes & Endocrinology confirmed that transdermal testosterone significantly improved sexual desire, arousal, and frequency of satisfying sexual events in postmenopausal women 12. The pooled effect size was moderate, with a mean increase of 0.85 satisfying sexual events per month over placebo. No oral TU formulation has been tested in women in a Phase III trial. Jatenzo's lowest available dose (158 mg) produces supraphysiological female testosterone levels, and no micro-dose capsule exists. Any off-label use in women requires compounding or dose modification that falls outside the studied pharmacokinetics.

Dr. Susan Davis, professor of women's health at Monash University and lead author of the Global Position Statement, has noted: "Oral testosterone preparations designed for men are not appropriate for women. The doses are too high, and the metabolic effects of oral androgens differ from transdermal delivery in females" 11. This represents a significant limitation for Jatenzo specifically, even as the broader testosterone-for-HSDD evidence base is reasonably strong.

Cognitive Function in Older Hypogonadal Men (Evidence Grade: C)

The TTrials cognitive function study found no significant improvement in verbal or visual memory, executive function, or spatial ability after 12 months of testosterone therapy in men over 65 with low testosterone and age-associated memory impairment 8. This was a disappointing result for proponents of testosterone as a cognitive intervention.

A smaller RCT (N=44) by Cherrier et al. found improvements in spatial memory and verbal fluency after 6 weeks of intramuscular testosterone enanthate in healthy older men 13. The discrepancy between these trials may reflect differences in baseline cognitive status, testosterone dosing, or treatment duration.

The current evidence does not support prescribing Jatenzo or any testosterone formulation primarily for cognitive enhancement. The Endocrine Society guideline explicitly recommends against testosterone therapy "for the purpose of improving cognitive function" 3. This off-label use carries Grade C evidence at best, and the risk-benefit ratio is unfavorable given the cardiovascular and hematologic monitoring burden.

Depressive Symptoms Associated with Hypogonadism (Evidence Grade: B)

A 2019 meta-analysis in JAMA Psychiatry (N=1,890 across 27 RCTs) found that testosterone treatment significantly reduced depressive symptoms compared to placebo, with larger effects in men who were hypogonadal at baseline and those receiving higher-dose regimens (effect size: g = 0.21 to 95% CI 0.10 to 0.32) 14.

The TTrials vitality sub-study showed a modest but significant improvement in the Patient Health Questionnaire (PHQ-9) depression score with testosterone gel versus placebo 8. The clinical significance of these small effect sizes remains debated. Testosterone is not a first-line antidepressant. The American Psychiatric Association does not include testosterone in its depression treatment algorithms.

Where testosterone therapy fits: as an adjunct in men with confirmed hypogonadism and comorbid depressive symptoms that have not fully responded to standard antidepressant therapy. Jatenzo's oral route may improve adherence in depressed patients who find injection routines burdensome. No RCT has examined Jatenzo specifically for this indication.

Cardiovascular Safety Across Off-Label Uses

Any off-label prescribing of Jatenzo must account for the TRAVERSE trial (N=5,246), the largest cardiovascular outcomes trial of testosterone therapy to date. Published in the New England Journal of Medicine in 2023, TRAVERSE found that transdermal testosterone gel did not increase the incidence of major adverse cardiovascular events (MACE) compared to placebo over a mean follow-up of 33 months (hazard ratio: 0.99 to 95% CI 0.81 to 1.21) 15.

This result was reassuring but not route-specific. Jatenzo carries a black box warning for blood pressure elevation not present on injectable or transdermal testosterone labels. The oral formulation's unique hepatic and lymphatic handling may produce distinct lipid effects: the Swerdloff trial observed HDL reductions of 3.2 mg/dL at steady state 1. Clinicians prescribing Jatenzo off-label should measure blood pressure at every visit and obtain a fasting lipid panel at baseline and 6 months.

Practical Prescribing Considerations for Off-Label Use

Jatenzo must be taken with food. Fasting administration reduces bioavailability by up to 80%, producing subtherapeutic testosterone levels regardless of the indication being treated 2. Patients who skip meals or follow intermittent fasting protocols are poor candidates for this formulation.

Dose titration follows the same algorithm for off-label and on-label use: start at 237 mg twice daily, check total serum testosterone (drawn 6 hours post-dose) after 2 weeks, and adjust in increments of 79 mg. The available capsule strengths are 158 mg, 198 mg, 237 mg, and 396 mg. Insurance coverage for off-label indications varies widely, and the average wholesale price exceeds $700 per month without prior authorization 2.

The minimum monitoring panel for any off-label Jatenzo use: serum testosterone (trough and 6-hour post-dose at baseline and titration visits), CBC with hematocrit, PSA (men over 40), fasting lipids, hepatic function, and seated blood pressure. Repeat labs at 3 months, 6 months, then every 6 to 12 months per Endocrine Society guidance 3.

Polycythemia (hematocrit > 54%) requires dose reduction or therapeutic phlebotomy. PSA velocity exceeding 1.4 ng/mL per year warrants urologic referral before continuing therapy.